PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2120294
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2120294
According to Mordor Intelligence, the Europe collagen market size is projected to be USD 4.64 billion in 2025, USD 4.94 billion in 2026, and reach USD 7.28 billion by 2031, growing at a CAGR of 8.08% from 2026 to 2031.European consumers are increasingly transitioning from reactive pharmaceutical solutions to preventive nutricosmetic routines that combine dermatology with nutrition science, which is driving demand for ingestible collagen across various age groups.

This report is Segmented by Source (Animal-Based, and Marine-Based), Form (Powder, and Liquid), Application (Food and Beverages, Dietary Supplements, Personal Care and Cosmetics, Pharmaceuticals, Animal Nutrition), and Geography (Germany, United Kingdom, Italy, France, Spain, Netherlands, Rest of Europe). The Market Forecasts are Provided in Terms of Value (USD).
Europe's demographic shift, characterized by the rapid growth of the 60-plus age group compared to the working-age population, is influencing supplement demand. The focus is shifting from multivitamins to targeted functional ingredients. According to data from the World Health Organization (WHO), by 2030, the global population aged 60 or older will reach 1.4 billion, representing a 34% increase from 2019 . Europe is contributing significantly to this trend due to low fertility rates and increased life expectancy. Joint-health formulations containing Type II collagen peptides are gaining popularity as orthopedic specialists increasingly recommend them to reduce reliance on non-steroidal anti-inflammatory drugs. In February 2024, Evonik plans to launch Vecollage Fortify L, a liquid collagen peptide aimed at improving joint mobility. This launch is supported by clinical evidence showing that a daily intake of 10 grams of hydrolyzed collagen can enhance cartilage synthesis markers within 12 weeks. Claims related to skin elasticity and dermal hydration are particularly appealing to the 50-plus female demographic, who view collagen as a non-invasive alternative to cosmetic procedures. While applications for hair and bone health are still emerging, they are attracting research and development investments, especially in formulations combining collagen with biotin, silica, and vitamin D3 for synergistic benefits.
National health systems in Germany, France, and the Netherlands are evaluating reimbursement models for preventive nutrition interventions. These regulatory developments support collagen supplements positioned for wellness maintenance rather than disease treatment. This shift is driven by financial pressures, as chronic musculoskeletal conditions place a significant burden on European healthcare systems. Policymakers are increasingly focusing on preventive measures to delay the onset of such conditions. Consumers are also adopting holistic wellness routines that integrate collagen with probiotics, adaptogens, and plant-based proteins. This trend signifies a move from single-ingredient supplementation to multi-functional product combinations. Gelita highlighted this development by presenting OPTIBAR and PeptENDURE at Food Ingredients Europe (Fi Europe) in December. These collagen peptides are tailored for sports nutrition and recovery, addressing the intersection of performance enhancement and preventive care. Furthermore, the expansion of telemedicine and personalized nutrition applications is enabling direct-to-consumer brands to offer collagen products alongside DNA-based dietary recommendations. This strategy bypasses traditional retail channels, allowing brands to achieve higher profit margins.
Animal-welfare advocacy groups in Germany and the United Kingdom (UK) are urging retailers to audit collagen supply chains for compliance with European Union (EU) Directive 98/58/EC on livestock protection. This has created reputational risks for brands unable to demonstrate humane slaughter practices. Bovine collagen sourced from cattle raised in intensive feedlots is facing boycotts from ethically conscious consumers, who prefer grass-fed or organic certifications despite their higher costs. Porcine collagen faces additional challenges due to religious and cultural restrictions, as Muslim and Jewish populations avoid porcine-derived products, limiting its market penetration in diverse urban centers such as London, Paris, and Berlin. Technological advancements, such as precision fermentation and recombinant collagen technologies, exemplified by Gelita's collaboration with Geltor, present opportunities for animal-free alternatives that replicate identical amino-acid sequences. However, as of 2026, commercial-scale production remains cost-prohibitive. Transparency initiatives, including blockchain-enabled traceability from farm to finished product, are emerging as competitive advantages. Nevertheless, the high implementation costs pose challenges for smaller suppliers. The ethical considerations surrounding collagen sourcing are becoming increasingly significant as younger consumers (aged 18 to 35) prioritize sustainability and animal welfare over price. This demographic shift is expected to influence sourcing strategies through 2031.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Animal-based collagen is projected to account for 66.14% of the European market volume in 2025, supported by well-established bovine and porcine supply chains and cost advantages ranging from 30% to 50% compared to marine alternatives. Bovine collagen, which is rich in Type I and Type III collagen, dominates applications in joint health and sports nutrition. Meanwhile, porcine collagen, known for its high glycine content, is preferred in cosmetic formulations aimed at improving skin elasticity. Marine-based collagen is anticipated to grow at a compound annual growth rate (CAGR) of 9.31% through 2031, driven by sustainability requirements and its perceived superior absorption due to smaller peptide sizes and a high concentration of Type I collagen.
Coastal nations such as Spain, Italy, and France are utilizing byproducts from the fishing industry to produce marine collagen, thereby reducing waste and adhering to certifications like the Aquaculture Stewardship Council and Friend of the Sea. These certifications enable premium pricing opportunities in Northern European markets. Emerging technologies, including precision fermentation and recombinant collagen production, represent a potential third category of collagen sources. Although still in the early stages of commercialization, these technologies could disrupt the traditional animal-versus-marine dichotomy by offering identical amino acid profiles without relying on animal inputs. For instance, Gelita's collaboration with Geltor highlights advancements in this area.